Update on the role of epothilones in metastatic breast cancer

Current Breast Cancer Reports

Volumn 5, Issue 1, 2013, Pages 51-56

  Hirsch, Bradford R ^a   Reed, Shelby D ^a   Lyman, Gary H ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Biomarkers; Chemotherapy; Cost; Epothilone; Ixabepilone; Metastatic breast cancer; Quality of life; Systemic therapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERIBULIN; FLUOROURACIL; IXABEPILONE; PACLITAXEL; SAGOPILONE; TAXANE DERIVATIVE; TRASTUZUMAB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; GENETIC ASSOCIATION; HEMATOLOGIC DISEASE; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NERVE CONDUCTION; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

EID: 84873447154     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-012-0095-3     Document Type: Article

References (56)

1. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973-9. (Pubitemid 47312861)
2. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat. 2010;119:621-31.
3. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2011;29:456-63. This study reported on the overall survival experienced by women with metastatic breast cancer across recent randomized trials.
4. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist. 2008;13:214-21. (Pubitemid 351679896)
5. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63:201-12.
6. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J. 2006;273:3301-10. (Pubitemid 43990933)
7. Food and Drug Adminstration: highlights of Ixempra prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2009/022065s001lbl.pdf. Accessed 1 Oct 2012
8. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP): recommendation for refusal of marketing authorization for ixabepilone. Available at: http://www.esmo.org/no-cache/view-news.html?x- ttnews[tt-news]=480&tx-ttnews[backPid]=585&cHash=9385b0342b. Accessed 1 Oct 2012
9. Cortes J, Vidal M. Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat. 2012;133(3):821-30.
10. Aghajanian C, Burris 3rd HA, Jones S, Spriggs DR, Cohen MB, Peck R, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007;25:1082-8. (Pubitemid 46596760)
11. Cristofanilli M. Advancements in the treatment of metastatic breast cancer (MBC): the role of Ixabepilone. J Oncol. 2012;2012:703858.
12. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-14. (Pubitemid 47310876)
13. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256-63.
14. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-7. (Pubitemid 350232252)
15. Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010;119:663-71.
16. Zubkus JD, Daniel DB, Eakle JF, et al. Neoadjuvant ixabepilone/ carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: a Sarah Cannon Research Institute phase II trial. J Clin Oncol. 2012;29s:(Abstract 621).
17. Plummer R, Woll P, Fyfe D, Boddy AV, Griffin M, Hewitt P, et al. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. Clin Cancer Res. 2008;14:8288-94.
18. Tolaney SM, Najita J, Chen W, et al. A phase II studyof ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Res. 2009;69s:(Abstract 3137).
19. Chuang E, Vahdat L, Caputo G, et al. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229. J Clin Oncol. 2007;25(18S):(Abstract 2570).
20. Roche H, De Benedictis E, Cottura E, Govi S, Dalenc F, Locatelli A, et al. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. Clin Breast Cancer. 2012;12:167-74.
21. Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly vs every 3 week ixabepilone plus bevacizumab (ixa/bev) vs paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol. 2010;28(15s):(Abstract 1040).
22. Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly vs every-3 week ixabepilone plus bevacizumab (ixa/bev) vs paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol. 2009;27(47s):(Abstract 1029).
23. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, Phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30(31):3841-7.
24. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:492-7.
25. Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol. 2012;23:53-8.
26. Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, et al. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer. 2011;105:1646-53.
27. Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, et al. A phase II trial evaluating 2 schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011;22:2411-6.
28. Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J, et al. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol. 2011;22:2144-9.
29. Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, et al. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer. 2012;107:808-13.
30. Kossoff EB, Ngamphaiboon N, Laudico TJ, O'Connor TL. Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Med Oncol. 2011;28 Suppl 1:S115-20.
31. Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly vs every-3-week ixabepilone plus bevacizumab (ixa/bev) vs paclitaxel plus bevacizumab (pac/bev) as first-line therapy for metastatic breast cancer (MBC):final results. J Clin Oncol. 2010;27(15s):(Abstract 1029).
32. Pavlick AC, Millward M, Farrell K, et al. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol. 2004; 22s (Abstract 7542).
33. Liu G, Wang W, Dipaola R, Carducci M, Wilding G. A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: a trial of the Eastern Cooperative Oncology Group (E3803). J Clin Oncol. 2006;24s:(Abstract 4618).
34. Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008;19:977-83. (Pubitemid 351627317)
35. Rugo HS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared with weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2012;30:(Abstract CRA1002).
36. Peacock NW, Yardley DA, Hendricks CB, et al. Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: a Sarah Cannon Research Institute phase II trial. J Clin Oncol. 2011;29s:(Abstract 1066).
37. Zubkus JD, Daniel DB, Eakle JF, et al. Neoadjuvant ixabepilone/ carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: a Sarah Cannon Research Institute phase II trial. J Clin Oncol. 2012;29s:(Abstract 621).
38. Campone M, Spielmann M, Wildier H. Safety profile of ixabepilone as adjuvant treatment for poor prognosis early breast cancer: first results of the unicancer-PACS 08 Trial [abstract P5-18-04]. Presented at San Antonio Breast Cancer Symposium San Antonio, USA; December 9, 2011; 2011.
39. Yardley DA, Hainsworth JD, Harwin WN, et al. TITAN: Ixabepilone vs weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. J Clin Oncol. 2011;29s:(Abstract 1103).
40. Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, et al. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast. 2012;21:89-94. This study reported on subset analyses of the previously published phase III studies, looking at patients who experienced early relapse. The study found a statistically significant progression free survival benefit favoring the combination of ixabepilone and capecitabine along with a trend toward improvement in overall survival.
41. Vahdat LT, Vrodoljak E, Gomez H, et al. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Clin Oncol. 2011;29s:(Abstract 1083).
42. Roche H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 2011;125:755-65.
43. Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011;11:376-83.
44. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer. 2011;11:139-45.
45. Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, et al. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer. 2012;118:461-8. This study assessed the balance of quantity and quality of life for the combination of ixabepilone and capecitabine compared with capecitabine alone using the Q-TWIST measurement tool. It found a statistically significant benefit in quality of life favoring the combination.
46. Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, et al. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res. 2011;71:3952-62.
47. Vahdat LT, Thomas ES, Roche HH, Hortobagyi GN, Sparano JA, Yelle L, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Official journal of the Multinational Association of Supportive Care in Cancer: Support Care Cancer. 2012;20(11):2661-8.
48. Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg JP, et al. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Res Treat. 2012;132:1035-47. This study reported on a gene expression analysis of breast cancer tumor cell lines, looking at predictors of therapeutic response to different microtubule-stabilizing agents.
49. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol. 2009;27:526-34.
50. Eschenbrenner J, Winsel S, Hammer S, Sommer A, Mittelstaedt K, Drosch M, et al. Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines. Front Oncol. 2011;1:44.
51. Reed SD, Li Y, Anstrom KJ, Schulman KA. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2009;27(13):2185-91.
52. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726-34. (Pubitemid 46179462)
53. Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007;25:3421-7. (Pubitemid 47310878)
54. Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415-20. (Pubitemid 47310877)
55. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine vs capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122:409-18.
56. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25(23):3399-406. (Pubitemid 47310875)